이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs (ENABLE-2)

2026년 11월 13일 업데이트: Enliven Therapeutics

A Phase 3, Multicenter, Open-Label, Randomized Study of ELVN-001 Versus Investigator-Selected Tyrosine Kinase Inhibitor (TKI) of Dasatinib, Nilotinib, or Bosutinib, in Adult Participants With Chronic Myeloid Leukemia in Chronic Phase (CP-CML), Previously Treated With One or More TKIs

The study is designed to compare the efficacy of ELVN-001 versus Investigator-selected tyrosine kinase inhibitor (TKI) for adults with previously treated chronic myeloid leukemia in the chronic phase (CP-CML). The Investigator-selected TKI will be one of the following standard of care therapies: Dasatinib, Nilotinib, or Bosutinib.

연구 개요

상세 설명

This is a multicenter, open-label, randomized study of ELVN-001 versus Investigator-selected TKI (Dasatinib, Nilotinib, or Bosutinib) in adult participants with CP-CML previously treated with one or more TKIs. Participants will be randomized to receive either ELVN-001 or their investigator's choice of one of the comparator TKIs (Dasatinib, Nilotinib, or Bosutinib). Treatment will continue until one of the protocol defined treatment discontinuation criteria are met. Participants will then enter a long-term follow-up period for survivorship and updates on disease status.

연구 유형

중재적

등록 (추정된)

450

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Georgia
      • Atlanta, Georgia, 미국, 30322
        • 모병
        • Winship Cancer Institute
    • Indiana
      • Indianapolis, Indiana, 미국, 46260
        • 모병
        • Investigative Clinical Research of Indiana, LLC
    • New Jersey
      • Morristown, New Jersey, 미국, 07960
        • 모병
        • Atlantic Health System
    • Utah
      • Ogden, Utah, 미국, 84405
        • 모병
        • Community Center Trials of Utah

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Male or female at least 18 years of age
  • Diagnosis of chronic myeloid leukemia in chronic phase (CP-CML)
  • Prior treatment with 1 or more BCR::ABL1 TKI(s)
  • Failure or intolerance on the immediate prior TKI
  • Adequate end organ function as measured by blood tests

Exclusion Criteria:

  • Known T315I mutation
  • Known second chronic phase of CML after previous progression to accelerated or blast phase
  • Any serious or uncontrolled medical disorder
  • QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec
  • Previous treatment with a hematopoietic stem-cell transplantation

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: ELVN-001

ELVN-001

ELVN-001 orally daily

활성 비교기: Investigator-selected TKI

Randomized to receive one of the following investigator's choice TKIs: Dasatinib, Nilotinib, or Bosutinib

TKI orally daily

다른 이름들:
  • 다사티닙
  • 닐로티닙
  • 보수티닙

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Major Molecular Response (MMR) Rate at Week 24 - ELVN-001 versus Investigator-selected TKI
기간: 24 weeks

Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale.

24 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
Major Molecular Response (MMR) Rate at Week 96 - ELVN-001 versus Investigator-selected TKI
기간: 96 weeks

Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale.

96 weeks
Change in overall scores, individual scales, and health status based on participant reporting - ELVN-001 versus Investigator-selected TKI
기간: planned total follow-up duration of 5 years

Validated questionnaires will be used to assess disease-related symptoms, functioning, and tolerability.

planned total follow-up duration of 5 years
Major Molecular Response (MMR) at all scheduled collection time points - ELVN-001 versus Investigator-selected TKI
기간: planned total follow-up duration of 5 years

Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale

planned total follow-up duration of 5 years
Major Molecular Response (MMR) by all scheduled collection time points - ELVN-001 versus Investigator-selected TKI
기간: planned total follow-up duration of 5 years

Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale

planned total follow-up duration of 5 years
Time to Major Molecular Response (MMR) - ELVN-001 versus Investigator-selected TKI
기간: planned total follow-up duration of 5 years

The time to MMR is defined as the time from the date of randomization to the date of the first documented occurrence of MMR

planned total follow-up duration of 5 years
Duration of Major Molecular Response (MMR) - ELVN-001 versus Investigator-selected TKI
기간: planned total follow-up duration of 5 years

Duration of MMR is defined as the time between the date of the first achievement of MMR and the earliest date of loss of MMR or CML-related death

planned total follow-up duration of 5 years
BCR::ABL1 ratio ≤ 1% at and by all scheduled data collection time points - ELVN-001 versus Investigator-selected TKI
기간: planned total follow-up duration of 5 years

BCR::ABL1 transcript levels are measured by quantitative polymerase chain reaction (qPCR). The ratio is calculated for BCR::ABL/ABL1 based on the International Scale

planned total follow-up duration of 5 years
Time to treatment failure - ELVN-001 versus Investigator-selected TKI
기간: planned total follow-up duration of 5 years

Time to treatment failure is defined as the time from randomization to the first date of any of the following events: treatment failure as defined per protocol

planned total follow-up duration of 5 years
Progression-free survival - ELVN-001 versus Investigator-selected TKI
기간: planned total follow-up duration of 5 years

Progression-free survival is defined as the time from randomization to the earliest occurrence of progression or death from any cause

planned total follow-up duration of 5 years
Overall survival (OS) - ELVN-001 versus Investigator-selected TKI
기간: planned total follow-up duration of 5 years

OS is defined as the time from randomization to death from any cause

planned total follow-up duration of 5 years
MR4 and MR4.5 at and by all scheduled data collection time points - ELVN-001 versus Investigator-selected TKI
기간: planned total follow-up duration of 5 years

Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MR4 is defined as a ratio BCR::ABL/ABL1 ≤ 0.01% on the International Scale and MR4.5 is defined as a ratio BCR::ABL/ABL1 ≤ 0.0032% on the International Scale

planned total follow-up duration of 5 years
Time to treatment discontinuation due to adverse event (AE) - ELVN-001 versus Investigator-selected TKI
기간: planned total follow-up duration of 5 years

This is defined as the time from randomization to discontinuation of study treatment due to an adverse event

planned total follow-up duration of 5 years
Characterization of adverse events (AE) and clinically relevant findings, including laboratory abnormalities, electrocardiogram (ECG) changes, and other safety data - ELVN-001 versus Investigator-selected TKI
기간: planned total follow-up duration of 5 years

Characteristics of AEs will be evaluated to assess safety and tolerability profiles

planned total follow-up duration of 5 years
Plasma concentrations of ELVN-001 in participants treated with ELVN-001 will be assessed at all scheduled collection timepoints
기간: planned total follow-up duration of 5 years

Relevant pharmacokinetic parameters will be evaluated

planned total follow-up duration of 5 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 31일

기본 완료 (추정된)

2028년 12월 31일

연구 완료 (추정된)

2033년 7월 1일

연구 등록 날짜

최초 제출

2026년 10월 23일

QC 기준을 충족하는 최초 제출

2026년 10월 23일

처음 게시됨 (실제)

2026년 10월 29일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 13일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다